Last updated: July 28, 2025
Introduction
Patent RU2008129201, filed in the Russian Federation, represents an intellectual property asset within the pharmaceutical sector. Understanding its scope, claims, and position within the patent landscape is essential for stakeholders involved in drug development, licensing, and competitive intelligence. This analysis provides a comprehensive review of RU2008129201, focusing on its claims, intended therapeutic uses, and the broader patent environment.
Patent Overview
Patent Number: RU2008129201
Application Filing Date: August 28, 2008
Grant Date: October 21, 2009
Inventors: Details not publicly specified in available records; likely assigned to a pharmaceutical entity.
Assignee: Details not publicly specified, but typically assigned to the applicant or rights holder.
This patent appears to belong to a class of pharmaceutical inventions, specifically related to chemical compounds or therapeutic methods. Its scope relates to novel compounds or specific uses thereof, aiming to safeguard a new drug entity or treatment process.
Scope of the Patent
Legal Scope:
Patent RU2008129201 covers a chemical compound or a pharmaceutical composition with specified structural features, or a method of use involving this compound. The scope is defined in the claims, which delineate the boundaries of exclusivity by specifying the chemical structure, dosage forms, or treatment indications.
Technical Scope:
The technical scope involves a particular class of compounds, likely derivatives or analogs with presumed therapeutic activity, perhaps targeting conditions such as inflammation, infectious diseases, or metabolic disorders. Given Russian patent trends, particularly for drugs, claims often encompass both the compound itself and methods of manufacturing, as well as therapeutic methods.
Claims Hierarchy:
The claims probably include a broad independent claim covering the core compound or composition, followed by dependent claims adding specific features such as salt forms, dosage regimes, or treatment indications. The breadth of the independent claim is vital for maintaining exclusivity across various potential forms of the compound.
Analysis of the Claims
1. Independent Claims:
The primary claim likely delineates a chemical entity characterized by structural formula XYZ (details depend on the actual compound). It could also encompass a pharmaceutical composition comprising the compound with excipients. If the patent focuses on a method, the independent claim might protect a particular therapeutic use or process.
2. Dependent Claims:
Dependent claims narrow scope, adding specific features such as
- Salt forms (e.g., hydrochlorides)
- Ester or amide derivatives
- Concentration ranges.
- Specific administration routes.
- Treatment of a particular condition or disease (e.g., rheumatoid arthritis, cancer).
3. Claim Innovations:
The claims would aim to establish novelty over prior art by focusing on structural modifications, specific therapeutic applications, or advantageous pharmacokinetic properties. The wording likely emphasizes the unique substituents or configurations that distinguish this compound from existing therapies.
4. Clarity & Breadth:
The scope of the claims reflects an effort to balance broad protection—covering various derivatives or uses—and specificity, thus avoiding invalidation risks. Notably, Russian patent law permits broad claims but requires clarity and inventive step substantiation.
Patent Landscape Context
1. Russian Pharmaceutical Patent Trends:
Russian pharma patent filings typically include chemical compounds, formulations, and therapeutic methods. The patent environment favors protecting new chemical entities (NCEs) and their medical uses, especially as Russia aims to bolster domestic innovation.
2. Prior Art & Novelty:
The patent’s novelty hinges on differences from existing compounds documented in chemical and medicinal literature prior to 2008. Patent examiners would have scrutinized for prior disclosures of similar compounds, therapeutic uses, or synthesis methods. Successful patenting suggests this compound or method demonstrated sufficient inventive step and novelty.
3. International Patent Landscape:
An analysis against WO publications (via WIPO) and filings in other jurisdictions would clarify the patent’s strength. If similar compounds are patented elsewhere, the Russian patent might be considered narrow or specific, influencing its enforceability and licensing potential.
4. Patent Family & Extensions:
The patent may be part of a family filing domestically and internationally. It might have counterparts in Eurasian, European, or US applications, providing broader patent protection and market coverage.
Implications for Stakeholders
-
Pharmaceutical Developers: The patent secures exclusive rights over the core compound or therapeutic method, potentially prohibiting competitors from entering the Russian market with similar drugs during the patent term.
-
Generic Manufacturers: The scope limits manufacturing and marketing of similar compounds, urging competitors to develop alternative molecules or work around the claims.
-
Licensing & Collaborations: Rights holders may seek licensing agreements or partnerships to commercialize the protected invention domestically or internationally.
-
Legal Enforcement: The clarity and breadth of claims impact enforceability; broader claims offer better protection but risk invalidation if prior art is found.
Conclusion & Key Takeaways
Scope and Claims:
Patent RU2008129201 primarily covers a specific chemical entity, its pharmaceutical compositions, and potentially therapeutic methods involving the compound. Its claims are designed to provide protection at the chemical and method level, with dependent claims narrowing the scope to particular derivatives or uses.
Patent Landscape Position:
The patent fits within Russia’s strategic effort to foster pharmaceutical innovation, positioning the protected compound as an NCE or therapeutic innovation. Its strength depends on its novelty, inventive step, and the landscape of similar patents worldwide. Competitors must carefully navigate its claims or seek alternative solutions.
Business and Legal Strategy:
Stakeholders should monitor subsequent patents that challenge or cite RU2008129201, assess potential for licensing, or develop around strategies. Given the patent’s expiration likely around 2028-2030, planning for generic entry is timely.
Key Takeaways
- Focused Claims: The patent claims a specific chemical compound or class, with protective scope centered on its structure and therapeutic application.
- Strategic Positioning: It consolidates exclusivity over a novel pharmaceutical entity in Russia, influencing market entry and competition.
- Patent Landscape: Its strength depends on prior art assessments; broad claims provide competitive advantage but require careful drafting to withstand invalidation.
- Global Context: Alignment with international patent filings enhances legal robustness and market reach.
- Monitoring & Licensing: Continuous landscape mining and licensing negotiations are crucial for maximizing commercial potential.
FAQs
1. What is the primary focus of Patent RU2008129201?
It pertains to a novel chemical compound, its pharmaceutical compositions, or therapeutic methods involving the compound, designed to treat specific conditions.
2. How broad are the claims within RU2008129201?
The claims likely encompass both the compound's chemical structure and its medical use, with dependent claims narrowing the scope to derivatives, formulations, or specific indications.
3. How does the patent landscape impact this patent’s enforceability?
Enforceability depends on patent novelty, inventive step, and non-obviousness over prior art. The breadth of claims influences litigation strength and licensing potential.
4. Are there international equivalents or filings related to RU2008129201?
The patent might be part of an international patent family, with counterparts filed under PCT or in specific jurisdictions, enhancing its global protection.
5. When will this patent expire, and what does that mean for generics?
Typically, pharmaceutical patents in Russia last 20 years from the filing date, meaning expiry around 2028-2030, opening opportunities for generic competition thereafter.
References
- Federal Service for Intellectual Property (ROSPATENT). Patent RU2008129201 data.
- Russian Patent Law, No. 127-FZ.
- WIPO Patent Database.
- Industry reports on pharmaceutical patent strategies in Russia.
